Health and Quality of Life Outcomes

Table 2 ACTS Burdens and Benefits scales: scale-level data quality, scaling assumptions, targeting and reliability

From: The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients

	Acceptability				Targeting			Reliability
	Item missing data (%)^a	Possible range (midpoint)	Actual score range	Mean score (SD)	Floor/ceiling effects (%)^b	Skewness	Cronbach’s alpha	Test-retest^c	Mean IIC^d	Range IIC
EINSTEIN DVT dataset
Dutch version (n=332)
ACTS Burdens	4	12–60 (36)	34–60	53.4 (5.45)	0/10	–0.99	0.79	0.95	0.24	0.03–0.69
ACTS Benefits	1	3–15 (9)	3–15	10.5 (2.20)	1/3	−0.77	0.80	0.72	0.56	0.46–0.66
Italian version (n=217)
ACTS Burdens	4	12–60 (36)	33–60	52.4 (6.26)	0/12	−0.78	0.90	0.94	0.43	0.25–0.83
ACTS Benefits	1	3–15 (9)	3–15	10.7 (2.15)	1/8	0.03	0.90	0.94	0.75	0.68–0.79
French version (n=222)
ACTS Burdens	4	12–60 (36)	33–60	55.6 (4.97)	0/14	−1.35	0.89	0.95	0.40	0.23–0.70
ACTS Benefits	3	3–15 (9)	3–15	11.5 (2.40)	2/12	−0.89	0.86	0.76	0.68	0.60–0.72
German version (n=243)
ACTS Burdens	5	12–60 (36)	34–60	52.0 (5.91)	0/7	−0.86	0.84	0.98	0.29	0.04–0.86
ACTS Benefits	1	3–15 (9)	3–15	12.2 (2.15)	2/12	−1.97	0.82	0.91	0.60	0.56–0.67
English version (n=322) ^e
ACTS Burdens	0	12–60 (36)	23–60	51.6 (6.78)	0/7	−1.12	0.86	0.98	0.36	0.12–0.67
ACTS Benefits	0	3–15 (9)	3–15	11.4 (2.50)	1/14	−0.62	0.87	0.91	0.70	0.59–0.74

^aLess than 0.5% missing data rounded to 0. ^bCalculated as the percentage of people scoring either 12 (floor) or 60 (ceiling) on the ACTS Burdens scale or 3 (floor) or 15 (ceiling) on the ACTS Benefits scale. ^cTest-retest between two administrations at 12 weeks. ^dRepresenting homogeneity. ^eUK, US, Canada.
ACTS Anti-Clot Treatment Scale, IIC item-item correlation, SD standard deviation, VTE venous thromboembolism.

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com